Unknown

Dataset Information

0

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.


ABSTRACT: We assessed infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility breakpoint predicts outcome. Treatment was successful in 10 of 11 nonurinary infections from susceptible strains and in 2 of 6 infections with MICs of >16/4 mug/ml. All six urinary infections responded to treatment regardless of susceptibility.

SUBMITTER: Gavin PJ 

PROVIDER: S-EPMC1479103 | biostudies-literature | 2006 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.

Gavin Patrick J PJ   Suseno Mira T MT   Thomson Richard B RB   Gaydos J Michael JM   Pierson Carl L CL   Halstead Diane C DC   Aslanzadeh Jaber J   Brecher Stephen S   Rotstein Coleman C   Brossette Stephen E SE   Peterson Lance R LR  

Antimicrobial agents and chemotherapy 20060601 6


We assessed infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility breakpoint predicts outcome. Treatment was successful in 10 of 11 nonurinary infections from susceptible strains and in 2 of 6 infections with MICs of >16/4 mug/ml. All six urinary infections responded to treatment regardless of susceptibility. ...[more]

Similar Datasets

| S-EPMC1563546 | biostudies-literature
| S-EPMC3165602 | biostudies-literature
| S-EPMC3697383 | biostudies-literature
| S-EPMC9487465 | biostudies-literature
| S-EPMC9615022 | biostudies-literature
| S-EPMC9410668 | biostudies-literature
| S-EPMC10994818 | biostudies-literature
| S-EPMC4217673 | biostudies-literature
2017-12-11 | PXD005587 | Pride
| PRJNA476828 | ENA